Scendea is an international product development and regulatory consulting group serving the pharmaceutical and biotechnology industry.
We are committed problem solvers, redefining the meaning of customer service, with a focus on reducing time-to-market and minimising development costs. Our scientific excellence, industry experience, and collaborative approach enable us to deliver high-quality innovative solutions aligned with jurisdiction-specific regulatory requirements.

Scendea’s international team, based in the US, UK, Netherlands, and Australia, offers strategic and operational support in the fields of Non-Clinical, CMC, Clinical, and Regulatory to successfully guide products from early development to marketing approval. We have extensive experience supporting the development of monoclonal antibodies (mAbs) across a wide range of indications and procedures. In addition, our team has worked with novel antibody derivatives such as fAbs and dAbs, bi- and trispecific molecules, antibody-drug conjugates, radiolabelled antibodies, and biosimilars in most regulatory pathways.

At Scendea, we collaborate, innovate, and together with our clients, we succeed.